查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714714

基因治療市場按載體類型、治療方式、目標基因組、遞送方式、給藥途徑、患者類型、治療領域和最終用戶分類－2025-2030 年全球預測

Gene Therapy Market by Vector Type, Treatment Modality, Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年基因治療市場價值將達82.9億美元，2024年將達到103.1億美元，複合年成長率為27.15%，到2030年將達到446.1億美元。

主要市場統計數據
基準年2023年 82.9億美元
預計2024年 103.1億美元
預測年份 2030 446.1億美元
複合年成長率（%） 27.15%

基因治療已迅速從理論上的可能性上升為治療複雜疾病的實踐基石。基因組編輯、載體開發和治療策略的進步為治療曾經被認為無法治癒的疾病開闢了前所未有的途徑。在這種技術不斷創新的環境中，公司正在利用基因治療的潛力直接針對基因異常。公共和私人投資的廣泛研究正在為市場核准和全球採用鋪平道路。

本報告概述了基因治療產業的現狀，並討論了繼續影響產業格局的關鍵趨勢、技術突破和監管發展。重點是確定臨床成功、挑戰和未來方向。對市場動態和新興模式的徹底檢查揭示了一個引人入勝的轉變故事，其中科學嚴謹性與富有同情心的關懷相遇。尖端生物技術與可靠臨床資料的融合凸顯了基因治療的變革潛力，並將讀者帶入個人化醫療成為常態的未來。

這種背景促使從研究人員到決策者的相關人員重新評估傳統策略。本書經過精心編寫，闡明了推動基因療法突破的宏觀趨勢和細節。這項全面的分析將深入了解支撐該行業快速發展的技術創新、監管和市場動態之間的相互作用。

改變基因治療市場

基因治療領域經歷了一場變革性的轉變，重新定義了醫療保健服務的模式。 CRISPR 等基因編輯技術的進步正在加快研究人員糾正遺傳疾病的速度，為傳統治療失敗的地方帶來希望。該領域的快速發展是由學術進步和產業投資之間的共生關係所推動的，並不斷突破醫學上可能的界限。

從傳統治療轉向更有針對性的基因介入帶來了顯著的進步。一系列應用的臨床試驗提供了改善患者治療效果的有力證據，促使人們重新關注精準醫療。這種轉變不僅需要改變臨床通訊協定，還需要重新評估監管環境以適應創新治療方法。因此，監管機構正在不斷調整其流程，以確保快速接觸患者並進行嚴格的安全評估。

此外，生物技術與資料分析和人工智慧的結合使得高效發現有前景的治療候選藥物成為可能。這種綜合方法有助於減少藥物開發所需的時間和成本，並加速從實驗室突破性發現到臨床的進程。隨著基因療法持續受到關注，市場參與企業正在利用這些進步，重新調整研究重點並投資下一代技術，以進一步提高治療性介入的有效性和安全性。

基因治療市場的關鍵細分洞察

對基因治療市場的詳細分析強調了涵蓋技術和治療應用多樣性的細緻細分策略的重要性。根據載體類型進行細分，揭示了非病毒載體和病毒載體之間的二分法。在非病毒載體領域，脂質轉染和質體DNA等遞送機制由於其易於使用和相對簡單的製造過程而受到歡迎。另一方面，病毒載體，如腺結合病毒（AAV）、腺病毒、單純皰疹病毒（HSV）和逆轉錄病毒載體，具有更高的轉導效率和持續的基因表現，使其對慢性疾病具有吸引力。

在考慮治療方法時，區分生殖細胞療法和體細胞療法非常重要。種系治療有可能從根本上糾正基因錯誤，但它仍然存在爭議且受到嚴格監管。相較之下，以基因增強和基因抑制技術為主的體細胞治療因風險相對較低、臨床應用較為簡便，發展勢頭強勁。這些技術可以有針對性地改變疾病的根本原因，而無需改變個體的基因組成。

進一步的細緻洞察延伸至有針對性的基因組修飾，其中焦點已在 DNA 和 RNA 修飾之間轉移。例如，RNA技術的創新對於快速解決病毒感染和代謝紊亂等病症至關重要，而傳統的DNA修飾技術對於長期治療解決方案仍然至關重要。此外，按給藥方式和給藥途徑進行分類進一步細化了市場格局。人們已經對體外和體內輸送系統以及肌肉注射、眼內注射和靜脈注射等給藥途徑進行了嚴格評估，每種給藥途徑在功效和患者依從性方面都具有獨特的優勢。

此外，根據患者類型和治療領域進行的細分提供了市場需求的全面概況。成人和兒科患者群體之間的差異使得可以製定有針對性的治療策略，而涵蓋心血管、感染疾病、單病和腫瘤疾病的治療領域則概述了具體的臨床挑戰。例如，將心血管疾病分為冠狀動脈疾病和心臟衰竭表明每個患者都需要量身定做的基因治療。類似的粒度適用於感染疾病，其中乙肝和愛滋病毒受到市場的廣泛關注。從囊腫纖維化到血友病和鐮狀細胞性貧血等單一疾病的分析凸顯了精準醫療的迫切需要，而腫瘤疾病分為骨髓惡性腫瘤和固態腫瘤，每種疾病都需要針對性的治療方法。

最後，基於受託研究機構、醫院和診所、製藥和生物技術公司以及研究機構等最終用戶的細分反映了基因療法開發和商業化的動態格局。這種多方面的細分方法有助於更深入地了解市場趨勢，並使相關人員能夠根據有針對性的治療方法、人口統計和技術標準部署複雜的策略。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球遺傳疾病和罕見疾病的發生率不斷上升，推動了對基因治療的需求。
      • 增加公共和私人資助舉措以支持臨床試驗
      • 改進法規結構，加速創新基因療法的核准流程
    • 限制因素
      • 基因治療費用高昂
    • 機會
      • 利用人工智慧和機器學習簡化基因治療研發流程
      • CRISPR 和其他基因編輯技術的持續創新
    • 任務
      • 與基因治療相關的操作問題
  • 市場區隔分析
    • 載體類型：腺結合病毒在眼科疾病和神經系統疾病的廣泛應用
    • 治療方法：體細胞療法因其安全性和監管可接受性而得到更廣泛的採用
    • 標靶基因組學：透過更快的控制通訊協定快速擴大RNA修飾的影響
    • 遞送方式：體內遞送由於其不受限制的應用而越來越受到青睞。
    • 給藥途徑：靜脈注射擴大用於治療各種遺傳性疾病
    • 患者類型：成人遺傳疾病的高發生率導致成年患者使用基因治療的情況增加。
    • 治療領域：感染疾病流行需要強大的基因治療
    • 最終用戶：製藥和生物技術公司在基因治療創新中的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 基因治療市場（依載體型）

  • 非病毒載體
    • 脂質體轉染
    • 質體DNA
  • 病毒載體
    • 腺結合病毒（AAV）載體
    • 腺病毒載體
    • 單純皰疹病毒（HSV）載體
    • 逆轉錄病毒載體

第7章 基因治療市場（治療方法類型）

  • 種系治療
  • 體細胞療法
    • 基因增強療法
    • 基因抑制療法

8. 針對基因組的基因治療市場

  • DNA修飾
  • RNA修飾

第9章基因治療市場（以交付方式）

  • 體外
  • In vivo

第 10 章 基因治療市場（依給藥途徑）

  • 肌肉注射
  • 眼
  • 靜脈

第 11 章 基因治療市場（依患者類型）

  • 成年患者
  • 兒科患者

第12章 基因治療市場（依治療領域）

  • 心血管疾病
    • 冠狀動脈疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 單基因疾病
    • 囊腫纖維化
    • 血友病
    • 鐮狀細胞性貧血
  • 腫瘤疾病
    • 造血系統惡性腫瘤
    • 固態腫瘤

第13章 基因治療市場（按最終用戶）

  • 合約研究組織
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第 14 章：美洲基因治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

15. 亞太地區基因治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

16. 歐洲、中東和非洲基因治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第17章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis SA
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • ViGeneron GmbH
  • Voyager Therapeutics Inc.
Product Code: MRR-437517DB6C62

The Gene Therapy Market was valued at USD 8.29 billion in 2023 and is projected to grow to USD 10.31 billion in 2024, with a CAGR of 27.15%, reaching USD 44.61 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 8.29 billion
Estimated Year [2024] USD 10.31 billion
Forecast Year [2030] USD 44.61 billion
CAGR (%) 27.15%

Gene therapy has rapidly ascended from a theoretical possibility to a practical cornerstone in the treatment of complex diseases. The ongoing evolution in genomic editing, vector development, and therapeutic strategies has opened unprecedented avenues in treating conditions once deemed incurable. In this environment of relentless innovation, companies harness the potential of gene therapy to target genetic anomalies directly. Extensive research, fueled by both public and private investment, is shaping the path to market approval and global adoption.

This report encapsulates the current state of the gene therapy industry while discussing key trends, technological breakthroughs, and regulatory frameworks that continue to reshape the landscape. Emphasis is placed on the delineation of clinical successes, challenges, and future directions. A thorough exploration of the market dynamics and emerging patterns reveals a compelling narrative of transformation, where scientific rigor meets compassionate care. The integration of advanced biotechnologies with robust clinical data underscores the transformative potential of gene therapy and invites the reader to envision a future where personalized medicine becomes the norm.

Against this backdrop, stakeholders ranging from researchers to decision-makers are encouraged to re-evaluate conventional strategies. The discussion is carefully structured to provide clarity on both the macro trends and fine-grained details that drive breakthroughs in gene therapy. As you navigate through the comprehensive analysis presented here, you will gain insights into the interplay of innovation, regulation, and market dynamics that underpin the sector's rapid progression.

Transformative Shifts in the Gene Therapy Landscape

The gene therapy sector has experienced transformative shifts that redefine the paradigms of healthcare delivery. Advancements in gene editing technologies such as CRISPR have accelerated the pace at which researchers can correct genetic disorders, offering hope where traditional treatments have failed. The rapid development in this field is driven by a symbiotic relationship between academic advancements and industrial investments, consistently pushing the boundaries of what is medically possible.

A notable evolution stems from the transition from conventional treatments to more targeted genetic interventions. Clinical trials across various applications have provided compelling evidence of improved patient outcomes, fueling a renewed focus on precision medicine. This shift is not only changing clinical protocols, but it also necessitates a reassessment of the regulatory landscape to accommodate innovative therapeutic methods. Consequently, regulatory agencies are increasingly adapting processes to ensure both rapid patient access and rigorous safety evaluations.

Moreover, the convergence of biotechnology with data analytics and artificial intelligence has enabled the efficient discovery of promising therapeutic candidates. This integrated approach is instrumental in reducing the time and cost associated with drug development, thus accelerating the journey from laboratory breakthroughs to clinical reality. As gene therapy continues to garner attention, market participants are reaping the benefits of these advancements by realigning their research priorities and investing in next-generation technologies that further enhance the efficacy and safety of therapeutic interventions.

Key Segmentation Insights in Gene Therapy Markets

A detailed analysis of the gene therapy market underscores the importance of a nuanced segmentation strategy that encapsulates the diversity of technological and therapeutic applications. The segmentation based on vector type reveals a bifurcation between non-viral and viral vectors. Within the realm of non-viral vectors, delivery mechanisms such as lipofection and plasmid DNA have gained traction due to their ease of use and comparatively simple production processes. Meanwhile, viral vectors, including adeno-associated virus (AAV), adenovirus, herpes simplex virus (HSV), and retrovirus vectors, offer higher transduction efficiencies and sustained gene expression, making them attractive for chronic conditions.

When considering treatment modality, the distinction between germline therapy and somatic cell therapy becomes crucial. Germline therapy, which has the potential to correct genetic errors at a fundamental level, remains controversial and heavily regulated. In contrast, somatic cell therapy, primarily focused on gene augmentation and gene suppression techniques, continues to gain momentum due to its relatively lower risk profile and more straightforward clinical applications. These methodologies allow for modifications that target the underlying cause of disease without altering the hereditary genetic makeup.

Further segmentation insights extend to target genome modifications, where the focus shifts between DNA and RNA modifications. Innovations in RNA technology, for instance, are proving pivotal in rapidly addressing conditions such as viral infections and metabolic disorders, while traditional DNA modification techniques remain essential for long-term therapeutic solutions. Additional layers of categorization through delivery mode and route of administration further refine the market landscape. Ex vivo and in vivo delivery systems are critically evaluated alongside administration routes such as intramuscular, intraocular, and intravenous methods, each offering distinct advantages in terms of efficacy and patient compliance.

Additional segmentation based on patient type and therapeutic area provides a comprehensive overview of market demand. Differentiating between adult and pediatric patient populations ensures targeted treatment strategies, while therapeutic segments spanning cardiovascular diseases, infectious diseases, monogenic disorders, and oncological conditions outline specific clinical challenges. The classification of cardiovascular conditions into coronary artery disease and heart failure, for example, highlights the specific demand for tailored gene therapy interventions. Similar granularity is applied to infectious conditions, with hepatitis B and HIV capturing significant market attention. The analysis of monogenic disorders-ranging from cystic fibrosis to hemophilia and sickle cell anemia-underscores the critical need for precision therapies, whereas oncological disorders are dissected into hematological malignancies and solid tumors, each demanding bespoke treatment modalities.

Finally, segmentation based on end-users, including contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes, reflects the dynamic landscape of gene therapy development and commercialization. This multi-dimensional segmentation approach supports a deeper understanding of market trends, enabling stakeholders to deploy refined strategies based on targeted therapeutic, demographic, and technological criteria.

Based on Vector Type, market is studied across Non-Viral Vectors and Viral Vectors. The Non-Viral Vectors is further studied across Lipofection and Plasmid DNA. The Viral Vectors is further studied across Adeno-Associated Virus (AAV) Vectors, Adenovirus Vectors, Herpes Simplex Virus (HSV) Vectors, and Retrovirus Vectors.

Based on Treatment Modality, market is studied across Germline Therapy and Somatic Cell Therapy. The Somatic Cell Therapy is further studied across Gene Augmentation Therapy and Gene Suppression Therapy.

Based on Target Genome, market is studied across DNA Modification and RNA Modification.

Based on Delivery Mode, market is studied across Ex Vivo and In Vivo.

Based on Route of Administration, market is studied across Intramuscular, Intraocular, and Intravenous.

Based on Patient Type, market is studied across Adult Patients and Pediatric Patients.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Monogenic Disorders, and Oncological Disorders. The Cardiovascular Diseases is further studied across Coronary Artery Disease and Heart Failure. The Infectious Diseases is further studied across Hepatitis B and HIV. The Monogenic Disorders is further studied across Cystic Fibrosis, Hemophilia, and Sickle Cell Anemia. The Oncological Disorders is further studied across Hematological Malignancies and Solid Tumors.

Based on End-User, market is studied across Contract Research Organizations, Hospitals & Clinics, Pharmaceutical & Biotech Companies, and Research Institutes.

Key Regional Insights Shaping Global Gene Therapy Markets

Regional dynamics play a pivotal role in the evolution of the gene therapy market. The Americas have emerged as a dominant region where innovation and robust clinical pipelines drive significant market value. Collaborative efforts between regulatory bodies, academic institutions, and biotech companies have fostered a conducive environment for advanced clinical trials and accelerated product approvals. This progress underscores the region's commitment to integrating breakthrough therapies into mainstream healthcare.

Europe, the Middle East, and Africa bring a diverse set of regulatory frameworks and market maturities, which translate into a region characterized by both high innovation intensity and localized challenges. The region boasts world-class research facilities and a rich history of biomedical breakthroughs, thereby acting as a fertile ground for the translation of gene therapy from bench to bedside. Strategic collaborations and harmonized regulatory initiatives have been instrumental in bolstering market acceptance and patient access in these territories.

The Asia-Pacific region, with its rapidly growing economies and expanding healthcare infrastructure, offers fertile ground for future gene therapy advancements. Increasing investments in pharmaceutical R&D and technology adoption are accelerating the implementation of gene therapies, especially in countries where rising disposable incomes and enhanced healthcare systems are driving demand. As these regions continue to mature, they are likely to become significant contributors to the global gene therapy market, underscoring the importance of tailoring strategies to diverse regulatory and socio-economic environments.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Setting the Pace in Gene Therapy Innovation

The competitive landscape in gene therapy is punctuated by a range of visionary companies that are pushing the boundaries of medical science. Innovators like Abeona Therapeutics Inc. and Adaptimmune Therapeutics PLC are rapidly advancing novel therapeutic platforms that promise to redefine patient outcomes. Other industry pioneers, such as Adverum Biotechnologies, Inc. and AGC Biologics, focus on optimizing vector delivery systems and scalable manufacturing processes, accentuating the operational prowess required for market success.

Major players are also leveraging rich pipelines and strategic partnerships to build resilient portfolios focused on rare and common genetic disorders alike. Esteemed organizations including Alnylam Pharmaceuticals, Inc. and American Gene Technologies Inc. continue to invest in robust R&D activities, while Amgen Inc. and AnGes, Inc. harness state-of-the-art biotechnologies to enhance the safety and specificity of gene therapies. The likes of Astellas Pharma Inc. and Biogen Inc. are setting benchmarks in clinical innovation, further amplified by the disruptive potential of bluebird bio, Inc. and Cellectis S.A.

Companies such as CRISPR Therapeutics AG and Editas Medicine, Inc. are leading the charge in precision genome editing technologies, attracting keen investor interest and regulatory support alike. Larger conglomerates like Danaher Corporation and F. Hoffmann-La Roche Ltd. bring pharmaceutical might and expansive market reach, while industry stalwarts including Gilead Sciences, Inc. and Intellia Therapeutics refine the scientific rigour behind clinical trial designs. Ionis Pharmaceuticals, Inc., along with Johnson & Johnson and Merck KGaA, continues to expand their therapeutic horizons by integrating gene therapies into broader treatment regimens. Storied innovators like Mustang Bio, Inc. and Novartis AG are demonstrating remarkable agility in navigating the complex interplay of clinical innovation and commercial viability. The strategic visions of Orchard Therapeutics PLC, Poseida Therapeutics, Inc., and Sangamo Therapeutics, Inc. further illuminate pathways to market integration, with Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., Syncona Limited, ViGeneron GmbH, and Voyager Therapeutics Inc. rounding out a comprehensive tapestry of industry excellence.

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Adverum Biotechnologies, Inc., AGC Biologics, Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Pharma Inc., Biogen Inc., bluebird bio, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Intellia Therapeutics, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Merck KGaA, Mustang Bio, Inc., Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., Syncona Limited, ViGeneron GmbH, and Voyager Therapeutics Inc.. Actionable Recommendations for Industry Leaders

Industry leaders should focus on leveraging cutting-edge research and consolidating robust partnerships to accelerate market penetration. It is crucial to invest in scalable manufacturing processes that accommodate sophisticated vector development while ensuring quality control and compliance with evolving regulatory standards. Emphasis must be placed on establishing dynamic clinical trial frameworks that are adaptive to emerging scientific data and patient feedback, thereby shortening the timeline from discovery to approval.

Additionally, aligning with strategic innovation clusters and research consortiums can provide valuable insights into regional market dynamics and advanced technological trends. Leaders should also consider diversifying their pipelines by strategically targeting both prevalent and niche therapeutic areas, enabling a balanced portfolio that mitigates market risks. Embedding advanced digital analytics into every phase of the development process can facilitate data-driven decision making, ensuring that product lifecycles are optimized for both clinical efficacy and cost efficiency.

Finally, a proactive engagement with regulatory bodies and industry stakeholders is essential to anticipate shifts in policy and technological landscapes. By staying ahead of the curve through continual investment in innovation and fostering collaborative synergies, industry leaders can drive sustained growth and establish enduring competitive advantages in the gene therapy arena.

Conclusion: Embracing the Future of Transformative Therapeutics

In summary, the gene therapy market is positioned at the intersection of groundbreaking science and evolving clinical realities. The transformative shifts in technological innovation, regulatory modernization, and proactive industry collaboration signal a paradigm where precision medicine can truly revolutionize patient care. By embracing detailed segmentation insights, regional trends, and the diverse strategies of key industry players, stakeholders are equipped to navigate the complexities inherent in this ever-changing landscape.

A clear focus on patient-centric innovation, combined with strategic investments in technology and infrastructure, reaffirms a future where genetic anomalies can be addressed with unprecedented precision and efficacy. The collective momentum of the industry encapsulates a vision for a healthier, more resilient future where gene therapy is integral to mainstream medical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for gene therapy driven by rising prevalence of genetic and rare diseases worldwide
      • 5.1.1.2. Growing public and private funding initiatives supporting gene therapy clinical trials
      • 5.1.1.3. Improved regulatory frameworks accelerating the approval process for innovative gene therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the gene therapy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging AI and machine learning to streamline gene therapy research and development processes
      • 5.1.3.2. Ongoing innovations in CRISPR and other gene-editing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Operational concerns associated with the gene therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Vector Type: Significant adoption of adeno-associated viruses in ocular and neurological disorders
    • 5.2.2. Treatment Modality: Substantial traction of somatic cell therapy, driven by safer profiles and regulatory acceptability
    • 5.2.3. Target Genome: Burgeoning influence of RNA modification owing to their faster regulatory protocols
    • 5.2.4. Delivery Mode: Growing preference for in vivo delivery characterized by its non-restrictive application
    • 5.2.5. Route of Administration: Proliferating usage of the intravenous administration suitable for a broad spectrum of genetic disorders
    • 5.2.6. Patient Type: Increasing utilization of gene therapies among adult patients owing to the higher incidence of adult-onset genetic disorders
    • 5.2.7. Therapeutic Area: Rising prevalence of infectious diseases demands robust gene therapies
    • 5.2.8. End-User: Expanding importance of the pharmaceutical and biotech companies for gene therapy innovations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gene Therapy Market, by Vector Type

  • 6.1. Introduction
  • 6.2. Non-Viral Vectors
    • 6.2.1. Lipofection
    • 6.2.2. Plasmid DNA
  • 6.3. Viral Vectors
    • 6.3.1. Adeno-Associated Virus (AAV) Vectors
    • 6.3.2. Adenovirus Vectors
    • 6.3.3. Herpes Simplex Virus (HSV) Vectors
    • 6.3.4. Retrovirus Vectors

7. Gene Therapy Market, by Treatment Modality

  • 7.1. Introduction
  • 7.2. Germline Therapy
  • 7.3. Somatic Cell Therapy
    • 7.3.1. Gene Augmentation Therapy
    • 7.3.2. Gene Suppression Therapy

8. Gene Therapy Market, by Target Genome

  • 8.1. Introduction
  • 8.2. DNA Modification
  • 8.3. RNA Modification

9. Gene Therapy Market, by Delivery Mode

  • 9.1. Introduction
  • 9.2. Ex Vivo
  • 9.3. In Vivo

10. Gene Therapy Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intraocular
  • 10.4. Intravenous

11. Gene Therapy Market, by Patient Type

  • 11.1. Introduction
  • 11.2. Adult Patients
  • 11.3. Pediatric Patients

12. Gene Therapy Market, by Therapeutic Area

  • 12.1. Introduction
  • 12.2. Cardiovascular Diseases
    • 12.2.1. Coronary Artery Disease
    • 12.2.2. Heart Failure
  • 12.3. Infectious Diseases
    • 12.3.1. Hepatitis B
    • 12.3.2. HIV
  • 12.4. Monogenic Disorders
    • 12.4.1. Cystic Fibrosis
    • 12.4.2. Hemophilia
    • 12.4.3. Sickle Cell Anemia
  • 12.5. Oncological Disorders
    • 12.5.1. Hematological Malignancies
    • 12.5.2. Solid Tumors

13. Gene Therapy Market, by End-User

  • 13.1. Introduction
  • 13.2. Contract Research Organizations
  • 13.3. Hospitals & Clinics
  • 13.4. Pharmaceutical & Biotech Companies
  • 13.5. Research Institutes

14. Americas Gene Therapy Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Gene Therapy Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Gene Therapy Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
    • 17.3.1. Be Biopharma secures USD 82 million to propel innovative haemophilia B gene therapy into early trials
    • 17.3.2. Fiocruz and GEMMABio collaboration paves the way for affordable gene therapy solutions in Brazil
    • 17.3.3. An exclusive partnership between Astellas Pharma and AviadoBio transforms gene therapy landscape with AVB-101
    • 17.3.4. FDA clearance ushers in AAV vector-based immunotherapy VNX-101 for leukemia trials
    • 17.3.5. CPC launched MicroCNX ULT series for cell and gene therapy cryopreservation
    • 17.3.6. NHS pioneers global first with gene therapy Casgevy to transform thalassemia care
    • 17.3.7. Merck's acquisition of Mirus Bio signals strategic expansion in viral vector bioprocessing capabilities for advancing gene therapy solutions
    • 17.3.8. Pfizer's promising phase 3 trial outcomes highlight potential improvement in hemophilia A gene therapy
    • 17.3.9. Genezen strengthens its production capabilities with acquisition of uniQure's Massachusetts operations
    • 17.3.10. India revolutionizes cancer treatment with its first affordable indigenous CAR-T gene therapy, NexCAR19
    • 17.3.11. Kyowa Kirin expands rare disease gene therapy portfolio with dynamic acquisition of Orchard Therapeutics
    • 17.3.12. Novartis and Voyager Therapeutics partner to revolutionize gene therapy for genetic disorders
  • 17.4. Strategy Analysis & Recommendation
    • 17.4.1. F. Hoffmann-La Roche Ltd.
    • 17.4.2. Novartis AG
    • 17.4.3. Biogen Inc.
    • 17.4.4. Astellas Pharma Inc.

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Adverum Biotechnologies, Inc.
  • 4. AGC Biologics
  • 5. Alnylam Pharmaceuticals, Inc.
  • 6. American Gene Technologies Inc.
  • 7. Amgen Inc.
  • 8. AnGes, Inc.
  • 9. Astellas Pharma Inc.
  • 10. Biogen Inc.
  • 11. bluebird bio, Inc.
  • 12. Cellectis S.A.
  • 13. CRISPR Therapeutics AG
  • 14. Danaher Corporation
  • 15. Editas Medicine, Inc.
  • 16. F. Hoffmann-La Roche Ltd.
  • 17. Gilead Sciences, Inc.
  • 18. Intellia Therapeutics
  • 19. Ionis Pharmaceuticals, Inc.
  • 20. Johnson & Johnson
  • 21. Merck KGaA
  • 22. Mustang Bio, Inc.
  • 23. Novartis AG
  • 24. Orchard Therapeutics PLC
  • 25. Poseida Therapeutics, Inc.
  • 26. Sangamo Therapeutics, Inc.
  • 27. Sarepta Therapeutics, Inc.
  • 28. Sibiono GeneTech Co. Ltd.
  • 29. Syncona Limited
  • 30. ViGeneron GmbH
  • 31. Voyager Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GENE THERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. GENE THERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 23. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 27. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 32. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 33. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED STATES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED STATES GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED STATES GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED STATES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 170. AUSTRALIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 172. AUSTRALIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 174. AUSTRALIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. AUSTRALIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. AUSTRALIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 180. AUSTRALIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 182. AUSTRALIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 189. CHINA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 190. CHINA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 193. CHINA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 194. CHINA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. INDIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 200. INDIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 201. INDIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 202. INDIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 203. INDIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 204. INDIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 205. INDIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. INDIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. INDIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 208. INDIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 209. INDIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. INDIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 212. INDIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. INDONESIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 215. INDONESIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 216. INDONESIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 217. INDONESIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. INDONESIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 219. INDONESIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 220. INDONESIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. INDONESIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. INDONESIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 223. INDONESIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 224. INDONESIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. INDONESIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 226. INDONESIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 227. INDONESIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. JAPAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 230. JAPAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 231. JAPAN GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 232. JAPAN GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. JAPAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 234. JAPAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 235. JAPAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. JAPAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. JAPAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. JAPAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 239. JAPAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 240. JAPAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 241. JAPAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 242. JAPAN GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. MALAYSIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 245. MALAYSIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 246. MALAYSIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 247. MALAYSIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. MALAYSIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 249. MALAYSIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 250. MALAYSIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. MALAYSIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. MALAYSIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 253. MALAYSIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. MALAYSIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 255. MALAYSIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 256. MALAYSIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 257. MALAYSIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 260. PHILIPPINES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 262. PHILIPPINES GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 264. PHILIPPINES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. PHILIPPINES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. PHILIPPINES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 268. PHILIPPINES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 269. PHILIPPINES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 270. PHILIPPINES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 272. PHILIPPINES GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. SINGAPORE GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 275. SINGAPORE GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 276. SINGAPORE GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 277. SINGAPORE GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. SINGAPORE GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 279. SINGAPORE GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 280. SINGAPORE GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. SINGAPORE GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. SINGAPORE GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 283. SINGAPORE GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 284. SINGAPORE GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 285. SINGAPORE GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 286. SINGAPORE GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 287. SINGAPORE GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH KOREA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH KOREA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. SOUTH KOREA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SOUTH KOREA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 298. SOUTH KOREA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 299. SOUTH KOREA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 300. SOUTH KOREA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 301. SOUTH KOREA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 302. SOUTH KOREA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. TAIWAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 305. TAIWAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 306. TAIWAN GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 307. TAIWAN GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 308. TAIWAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 309. TAIWAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 310. TAIWAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 311. TAIWAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. TAIWAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 313. TAIWAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 314. TAIWAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 315. TAIWAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 316. TAIWAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 317. TAIWAN GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. THAILAND GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 320. THAILAND GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 321. THAILAND GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 322. THAILAND GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 323. THAILAND GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 324. THAILAND GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 325. THAILAND GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. THAILAND GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. THAILAND GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 328. THAILAND GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 329. THAILAND GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 330. THAILAND GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 331. THAILAND GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 332. THAILAND GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 333. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. VIETNAM GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 335. VIETNAM GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 336. VIETNAM GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 337. VIETNAM GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 338. VIETNAM GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 339. VIETNAM GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 340. VIETNAM GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 341. VIETNAM GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. VIETNAM GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 343. VIETNAM GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 344. VIETNAM GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 345. VIETNAM GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 346. VIETNAM GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 347. VIETNAM GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 348. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 350. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 351. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 352. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 353. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
  • TABLE 354. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 355. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 356. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2